GLPBio

Myelopeptide-2 (MP-2)

Catalog No.: GP10114Purity:>98.00%Synonyms: H2N-Leu-Val-Val-Tyr-Pro-Trp-OH
COASDSData Sheet
Myelopeptide-2 (MP-2) is an immunomodulator derived from porcine bone marrow cell culture supernatant.

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.

Myelopeptide-2 (MP-2)
Cas No.: 137833-31-9
1mgIn Stock
$31.00
1
5mgIn Stock
$89.00
1
10mgIn Stock
$157.00
1
25mgIn Stock
$207.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

Aucune citation n’est actuellement disponible pour ce produit. Vous trouverez ci-dessous une sélection de publications citant des produits GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Myelopeptide-2 (MP-2) is an immunomodulator derived from porcine bone marrow cell culture supernatant. Myelopeptide-2 restores the mitotic reactivity of human T lymphocytes suppressed by HL-60 leukemia cell conditioned medium or measles virus. Myelopeptide-2 can be used in studies on tumor immunosuppression recovery and antiviral immunotherapy[1-4].

In vitro, phytohemagglutinin-stimulated T lymphocytes were incubated with 100μg/mL Myelopeptide-2 and HL-60 cell conditioned medium for 72 hours. Myelopeptide-2 restored T lymphocyte proliferative response. Myelopeptide-2 restored CD3 and CD4 antigen expression and CD25-positive cell proportion[5]. T lymphocytes were treated with 10-25μg/mL Myelopeptide-2 for 18-24 hours. Myelopeptide-2 restored T lymphocyte cytotoxic activity against P-388 leukemia cells[6].

In vivo, urethane-induced BALB/c mice received 10μg/mouse Myelopeptide-2 by intraperitoneal injection daily for 4 days. Myelopeptide-2 reduced the number of spontaneous lung adenomas. Urethane-induced BALB/c mice received 100μg/mouse Myelopeptide-2 by intraperitoneal injection for 25 days. Myelopeptide-2 reduced animal mortality and delayed the first appearance time of lung tumors[7]. Female mice transplanted with Ca-755 cells, Lewis cells, or S180 cells received 0.5mg/kg Myelopeptide-2 by subcutaneous injection once daily for 5 times, or 1mg/kg or 2mg/kg every 96 hours for 2 times. Myelopeptide-2 inhibited transplanted tumor growth[8].

References:
[1] Petrov R. Myelopeptides: new immunoregulatory peptides. Allergy Proc. 1995 Jul-Aug;16(4):177-84.
[2] Sorokina NS, Starostina MV. Myelopeptides Reduce Morphine Tolerance in C57BL/6j Mice. Bull Exp Biol Med. 2021 Sep;171(5):623-626.
[3] Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, et al. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. J Immunother. 2006 May-Jun;29(3):306-12.
[4] Svirshchevskaya EV, Belevskaya RG, Roslavtzeva TA, et al. Influence of Myelopeptides on IL-1 and IL-2 Activities. Russ J Immunol. 1997 Apr;2(1):29-36.
[5] Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes suppression of T lymphocytes induced by human leukemia HL-60 cells. Immunol Lett. 1996 Jun;50(1-2):143-7.
[6] Khabarov SV, Gerasimova GK, Mikhailova AA, et al. Myelopeptide-2 Induces the Resistance of T-Lymphocytes to Tumor Suppression. Dokl Biol Sci. 2003;390:282-5.
[7] Mikhailova AA, Kirilina EA, Morozova OV, et al. Effect of Myelopeptide-2 on the Development of Spontaneous and Urethane-Induced Tumors in Mice. Bull Exp Biol Med. 2002 Jan;133(1):68-70.
[8] Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and Properties of the retro-Analogue of Myelopeptide MP-2. Russ J Bioorg Chem. 2005;31(3):210-5.

Protocole (Protocol)

Cell experiment [1]:

Cell lines

 human peripheral blood T lymphocytes

Preparation Method

 PHA-stimulated human T lymphocytes were cultured with 10%(v/v) HL-60 cell conditioned medium as suppressive substance, and Myelopeptide-2 was added at 0.1-100μg/mL simultaneously with or after 1h/24h exposure to HL-60 CM for 72h; [3H]thymidine incorporation and flow cytometry for CD3, CD4, and CD25 were then measured.

Reaction Conditions

 0.1-100μg/mL; 72h

Applications

 Myelopeptide-2 abolished HL-60 CM suppression of PHA-induced T lymphocyte proliferative response in a dose-dependent manner. Myelopeptide-2 restored CD3- and CD4-positive cell proportions and CD3- and CD4-positive fluorescence intensity, restored CD25-positive cell proportion reduced by HL-60 CM.
Animal experiment [2]:

Animal models

 female mice (linear and hybrid, 18-20g body mass)

Preparation Method

Mice were transplanted with Ca-755 adenocarcinoma of mammary gland, Lewis lung adenocarcinoma, or S180 sarcoma cells (50mg per mouse) on day 0. Starting from day 3 after transplantation, mice were treated with Myelopeptide-2 dissolved in isotonic solution by subcutaneous injection according to two schemes: 0.5mg/kg five times at 24h intervals, or 1mg/kg or 2mg/kg two times at 96h interval. Control mice received isotonic solution. Tumor volumes were measured on days 7, 14, and 18 after transplantation for calculation of dynamics of growth inhibition (DGT).

Dosage form

0.5-2mg/kg; s.c.; five times at 24h intervals or two times at 96h interval

Applications

Myelopeptide-2 inhibited the growth of Ca-755 adenocarcinoma of mammary gland, Lewis lung adenocarcinoma, and S180 sarcoma in mice.
References:
[1] Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes suppression of T lymphocytes induced by human leukemia HL-60 cells. Immunol Lett. 1996 Jun;50(1-2):143-7.
[2] Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and Properties of the retro-Analogue of Myelopeptide MP-2. Russ J Bioorg Chem. 2005;31(3):210-5.

Documents produit (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Propriétés chimiques (Chemical Properties)

N° CAS
137833-31-9
Synonymes
H2N-Leu-Val-Val-Tyr-Pro-Trp-OH
SMILES
N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CC(C=CC=C4)=C4N3)C(O)=O)=O)=O)=O)=O)=O
Formule moléculaire
C41H57N7O8
Masse moléculaire
775.93
Solubilité
≥77.5mg/mL in DMSO
Conservation
Store at -20°C
Conseils généraux
Choisissez un solvant adapté selon les données de solubilité du produit. Après préparation, répartissez la solution mère en aliquotes afin d’éviter les cycles répétés de congélation-décongélation.
Utilisez les solutions mères dans les 6 mois si elles sont conservées à -80°C, ou dans le mois si elles sont conservées à -20°C.
Pour améliorer la solubilité, réchauffez le tube à 37°C et soniquez-le pendant une durée appropriée.
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for Myelopeptide-2 (MP-2)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%